{"nctId":"NCT01151410","briefTitle":"An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age","startDateStruct":{"date":"2010-08"},"conditions":["Hypertension"],"count":208,"armGroups":[{"label":"Aliskiren","type":"EXPERIMENTAL","interventionNames":["Drug: Aliskiren"]},{"label":"Enalapril","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Enalapril"]}],"interventions":[{"name":"Aliskiren","otherNames":[]},{"name":"Enalapril","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* msSBP (mean of 3 systolic blood pressure measurements) must be ≥ 95th percentile for age, gender and height, at Visit 2 (randomization), in study CSPP100A2365\n* Must be ≥ 20 kg and ≤ 150 kg at Visit 2 (randomization), in study CSPP100A2365\n* Must be able to swallow minitablets (2mm in diameter) administered in soft food\n* Successful completion of Phase 1 (dose response phase) and at least 1 week of Phase 2 (placebo withdrawal phase) of the CSPP100A2365 protocol, with no serious drug-related adverse event(s).\n\nExclusion Criteria:\n\n* Patient receiving immunosuppressant medication (e.g. cyclosporine, MMF, etc) other than oral/topical steroids, for any medical condition\n* Current diagnosis of heart failure (NYHA Class II-IV) or history of cardiomyopathy or obstructive valvular disease\n* msSBP ≥ 25% above the 95th percentile\n* Second or third degree heart block without a pacemaker\n* AST/SGOT or ALT/SGPT \\>3 times the upper limit of the reference range\n* Total bilirubin \\> 2 times the upper limit of the reference range\n* Creatinine clearance \\< 30 mL/min/1.73m² (calculated using Modified Schwartz formula to estimate glomerular filtration rate \\[GFR\\]), based on the serum creatinine concentration obtained at the screening visit)\n* WBC count \\< 3000/mm³\n* Platelet count \\< 100,000/mm³\n* Serum potassium \\> 5.2 mEq/L\n* Other protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at to End of Study","description":"Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participants remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 2 to 3 minute intervals and the mean of three sSBP measurements were used as the average sitting office blood pressure for that visit.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.63","spread":"1.16"},{"groupId":"OG001","value":"-7.94","spread":"1.14"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study","description":"Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participants remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 2 to 3 minute intervals and the mean of three sDBP measurements were used as the average sitting office blood pressure for that visit.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.90","spread":"0.87"},{"groupId":"OG001","value":"-4.94","spread":"0.85"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Arterial Pressure (MAP) (mmHg) From Baseline to End of Study","description":"MAP was defined as the average arterial pressure during a single cardiac cycle. The MAP was measured as sum of diastolic blood pressure (DBP) and one third of difference between systolic blood pressure (SBP) and DBP i.e. MAP = DBP+1/3\\*(SBP--DBP).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.15","spread":"0.89"},{"groupId":"OG001","value":"-5.95","spread":"0.87"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":105},"commonTop":["Upper respiratory tract infection","Headache","Viral infection","Cough","Nasopharyngitis"]}}}